3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
13
Breast Neoplasms
11
Carcinoma, Transitional Cell
6
Carcinoma, Non-Small-Cell Lung
5
Urinary Bladder Neoplasms
4
Neoplasm Metastasis
4
Lung Neoplasms
3
Small Cell Lung Carcinoma
2
Urothelial Bladder Carcinoma
1
Salivary Gland Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Metastatic Urothelial Cancer
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Localized Muscle Invasive Bladder Urothelial Carcinoma
1
Liver Failure
1
HRD Cancer
1
Glioblastoma
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Drug-Related Side Effects and Adverse Reactions
1
Carcinoma, Small Cell
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Interventions
pembrolizumab
3
Paclitaxel
2
Carboplatin
2
ulixertinib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
selinexor
1
sapanisertib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
dostarlimab
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Vaginal Smears
1
VMBP protocol
1
Ultrasound, High-Intensity Focused, Transrectal
1
Trastuzumab
1
Sutures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Uterine Neoplasms
×
sacituzumab govitecan
×
90 days
×
Clear all
No trials found.